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Preclinical studies have demonstrated that the chemotherapeutic action of oxaliplatin, a third generation platinum derivative, is
improved when combined with cetuximab, a monoclonal antibody inhibitor of epidermal growth factor receptors. To explore the
mechanism of this synergistic benefit, we used HCT-8 and HCT-116, two human colon cancer cell lines, respectively, responsive and
non-responsive to the oxaliplatin/cetuximab combination. We examined the effect of drug exposure on glutathione-S-transferase-
mediated oxaliplatin detoxification, DNA–platinum adducts formation, cell cycle distribution, apoptosis, and the expression of
multiple targets involved in DNA replication, recombination, and repair. The major changes we found in HCT-8 were a stimulation of
oxaliplatin–DNA adduct formation associated with reduced expression of the key enzyme (excision repair cross complementation
group1: ERCC1) in the key repair process of oxaliplatin–DNA platinum adduct, the nucleotide excision repair (NER), both at the
mRNA and protein levels. We also observed a reduced expression of factors involved in DNA replication initiation, which correlates
with an enrichment of cells in the G1 phase of the cell cycle as well as an acceleration of apoptosis. None of these changes occurred
in the non-responsive HCT-116 cell that we used as a negative control. These findings support the fact that cetuximab potentiates
the oxaliplatin-mediated cytotoxic effect as the result of inhibition of NER and also DNA replication initiation.
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Colorectal cancer is the second leading cause of cancer-related
death in the western world. Even though progress has been made
in adjuvant chemotherapy, more than 50% of patients relapse or
present with metastatic disease at the time of diagnosis.
Oxaliplatin, a third-generation platinum analogue, showed
significant single-agent activity in advanced colorectal cancer.
Oxaliplatin-mediated cytotoxic effects result on DNA damages via
DNA platinum adducts formation. Despite recent improvement in
the field of systemic chemotherapy, one of the greatest issues
remains is drug resistance. Mechanisms of resistance to platinum
agents mainly involve a potentiation of the glutathione-S-
transferase (GST) detoxification system and/or DNA repair.
Elevated levels of GST have been demonstrated to render some
cancer cell types resistant against well-known platinum anticancer
drugs (Blyumenberg et al, 1996; Wernyj and Morin, 2004). Indeed,
platinum complexes are very reactive with the cysteine residue of
glutathione (GSH), which detoxifies these compounds by a rapid
binding mechanism. The nucleotide excision repair (NER) is the
main cellular process involved in the elimination of oxaliplatin–
DNA platinum adducts (Chaney et al, 2005) where excision repair
cross complementation group1 (ERCC1) is the key enzyme leading
to the 50 incision of the platinum DNA damage (Reed, 1998).
Excision repair cross complementation group1 exists as mRNA
and as protein in at least two forms. One form is the full length and
the second form is an alternatively spliced form (Yu et al, 1998).
Novel biological agents, such as cetuximab (C225, Erbitux
s), a
recombinant human/mouse monoclonal antibody against epider-
mal growth factor receptors (EGFR), have recently been shown to
improve the clinical benefit for patients with metastatic colorectal
cancer (Cunningham et al, 2004; Saltz et al, 2004). Epidermal
growth factor receptors is a member of HER tyrosine kinase
growth factor receptor family, involved in signalling pathways
affecting cellular growth, differentiation and proliferation (Car-
penter and Cohen, 1990). Colorectal cancer is frequently associated
with high expression levels of EGFR (25–80%) resulting in a more
aggressive disease and a poor prognosis (Porebska et al, 2000; Lee
et al, 2002). Moreover, it has been shown that cetuximab use can
partially reverse chemoresistance occurring during irinotecan
chemotherapy (Prewett et al, 2002).
It is now well documented that EGFR inhibition is involved in
resistance to cytotoxic drugs. Hence, the blockade of EGFR is a
promising strategy to improve colorectal cancer treatment.
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sWe previously demonstrated on a panel of human colorectal
cancer cell lines that cetuximab can enhance the antitumour
activity of oxaliplatin and the observed responses were strictly
dependent on the cell type, not correlated with the level of EGFR
expression but related to the basal level of phospho-EGFR. In this
previous work, we have shown that oxaliplatin combined with
cetuximab was synergistic in the HCT-8 cell line in vitro for
inhibition of cellular proliferation and in vivo for inhibition of
tumour growth, whereas the HCT-116 cell line remained
unresponsive (Balin-Gauthier et al, 2006).
However, the mechanisms responsible for the combined effects
of cetuximab with oxaliplatin remain unclear, as do the mechan-
isms involved in the reversion of drug resistance.
The aim of this study was to decipher the molecular basis of how
cetuximab enhances oxaliplatin’s antiproliferative effects; basi-
cally, how EGFR signalling pathway inhibition regulates oxaliplatin
pharmacology. To explore the mechanism of this synergistic
benefit, we used responsive (HCT-8) and non-responsive (HCT-
116) human colon cancer cell lines and we analysed the effect of
cetuximab treatment on oxaliplatin intracellular detoxification,
DNA adduct formation, cell cycle distribution, and induction of
apoptosis. We also performed a multigene analysis, by RT-qPCR,
to analyse the effect of additional cetuximab treatment on the
transcriptional expression of numerous genes involved in cell cycle
progression and DNA replication and repair. The results indicate
that cetuximab potentiates the oxaliplatin-mediated cytotoxic
effect through combined defects in NER and DNA replication
initiation.
MATERIALS AND METHODS
Drugs
Cetuximab (Erbitux, C225, 2mgml
 1) was kindly provided by
MERCK (Darmstadt, Germany) and oxaliplatin (Eloxatine
s,L -
OHP, 5mgml
 1) was purchased from Sanofi-Aventis (Gentilly,
France).
Cell lines
Human colon carcinoma cell lines HCT-116 and HCT-8 (American
Type Culture Collection, ATCC-LGC Promochem Sarl, Molsheim,
France) were routinely maintained in RPMI-1640 medium contain-
ing 5% fetal calf serum (FCS), supplemented with 2mML -
glutamine (Cambrex, Saint Beauzire, France) at 371C and under
5% CO2. Before any experiment, cells were cultured for 1 week in
phenol-red-free medium complemented as described previously.
Platinum adduct quantitation
Oxaliplatin–DNA adduct formation Exponentially growing cells
were treated with 5mM oxaliplatin with or without cetuximab
(20mgml
 1) for 24h. Cells were then washed twice with cold PBS
and frozen at  201C until analysis. DNA was extracted and DNA
platinum content analysis performed by atomic absorption
spectroscopy (AAS) as described below.
Oxaliplatin–DNA adduct repair Exponentially growing cells
were treated for 1h with 40mM oxaliplatin with or without
cetuximab (20mgml
 1). Following incubation, the cells were
washed twice with cold PBS and either frozen at  201C (T0) or
placed in a culture medium for 6 and 24h with 20mgml
 1 added
cetuximab for the combination treatment. For the 24-h time
points, the cells were incubated with 2.5mCi [
3H]-thymidine 24h
before oxaliplatin exposure to correct for DNA adduct concentra-
tions from replication. DNA was extracted and DNA platinum
content analysis performed by AAS as described below.
Platinum adduct analysis DNA from frozen samples was
extracted using the Flexigene Kit (Qiagen, Courtaboeuf, France)
following the manufacturer’s instructions. The samples were
stored at  201C and sonicated just before analysis.
Platinum (Pt) content was determined by AAS on an AAnalyst
600 (Perkin-Elmer, Courtaboeuf, France). A total of 20ml of DNA
solution was pipetted and the temperature increments were 1201C
for 20s, 1301C for 50s, 3501C for 20s, 5501C for 20s, and 14001C
for 20s. These steps were repeated four times and were followed by
further temperature increases to 23501C for 8s, 24501C for 4s,
201C for 10s, and 24501C for 4s. The reading wavelength was set to
265.9nm. Pt concentrations in the samples were calculated from a
standard curve (5.25–262.5ng Pt per ml). Concentrations deter-
mined at 6 and 24h after the end of incubation were corrected by
the ratio of thymidine incorporation between the start of the
incubation and the time points. Results (pg Pt per mg DNA) are
expressed as the mean±s.e.m. of six independent experiments.
Glutathione-S-transferase activity
The total GST activity was determined according to Habig et al
(1974). Briefly, 2 10
6 exponentially growing cells were plated in
100-mm Petri dishes and exposed to either oxaliplatin (5mM),
cetuximab (20mgml
 1), or a combination of both. After 6 and 24h
of exposure, the cells were harvested in cold PBS and centrifuged at
1200g for 10min. Pellets were resuspended in 1ml PBS and
sonicated for 30s in ice. After centrifugation at 15000g for 30min,
protein quantitation was performed on supernatants by the
Bradford method. The samples were stabilised with 100mlo f
50mgml
 1 bovine serum albumin and then incubated with
reduced GSH (2mM final concentration, Sigma, Saint-Quentin
Fallavier, France) for 2min at 301C. The reaction was started by
adding 1-chloro-2,4-dinitrobenzene (2mM final concentration).
The difference in absorbance at 340nm during the first 3min was a
linear function of the GST activity. Four absorbance measurements
were taken at 301C every 10s. Glutathione-S-transferase activity in
the samples was calculated from a standard curve (0.075–
10Uml
 1) obtained from serial dilutions of an equine GST stock
solution (40Umg
 1, Sigma).
Results (n¼3) are expressed as unit (U) of GST per mg protein
and represented as the mean±s.e.m. of variation factors of the
GST activity after drug exposure compared to GST activity of
untreated cells (variation factor¼1).
Western blotting analysis of ERCC1 expression
Cells were plated at 1.5 10
6 cells in 100-mm Petri dishes, and 24h
later they were exposed to 5mM oxaliplatin and/or 20mgml
 1
cetuximab for 24h. Cells were then harvested and lysed in specific
buffer (50mM Tris pH 7.4, 150mM NaCl, 1% Triton X, 0.1% SDS,
5m M MgCl2,5 0 m M NaF, 2mM PMSF, 10mM DTT, 2mM
orthovanadate, 5mgml
 1 sodium deoxycholate, 6.4mgml
 1 phos-
phate substrate, and Sigma 104
s). Cleared lysates were separated
on 12.5% SDS-polyacrylamide gels, blotted to PVDF membranes
(Amersham, Orsay, France), and incubated with specific anti-
bodies against ERCC1 and Tubulin beta (Neomarkers, Interchim,
Montlucon, France). Detection was performed using peroxidase-
conjugated secondary antibodies (Bio-Rad, Marnes la Coquette,
France) and an ECL
þ chemiluminescence detection kit (Amer-
sham Pharmacia Biotech, Orsay, France). The blots were scanned
and analysed with the molecular dynamics densitometer and
ImageQuant software. Results are representative of three indepen-
dent experiments.
Flow cytometric analysis of cell cycle phase distribution
Exponentially growing cells were plated at 10
5 cells in 100-mm
Petri dishes, and 24h later the cells were exposed to 5mM
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soxaliplatin, 20mgml
 1 cetuximab, or the combined treatment
according to three schedules of exposure: (1) 24-h exposure to
oxaliplatin followed by replacement of the medium by drug-free
medium until analysis; (2) simultaneous oxaliplatin and cetuximab
24-h exposure followed by cetuximab treatment alone (medium
and treatment were changed daily until analysis); and (3)
cetuximab alone renewed daily until analysis. At the time indicated
in the figure legends, media were collected and cells trypsinised
and pelleted by low-speed centrifugation (860g for 5min). Cells
were then washed twice in 0.5ml of cold PBS and fixed in 1.5ml of
ice-cold absolute ethanol for 1h at 41C, followed by staining with
propidium iodide (1mgml
 1). The DNA content was determined
with a FACScalibur flow cytometer (Becton Dickinson, San Jose,
CA, USA). Unless otherwise stated, the proportions of cells in G0/
G1, S, and G2/M phases of the cell cycle were calculated from their
DNA histogram using ModFit software (Becton Dickinson).
Results are representative of three independent experiments.
Fluorescence
Cells were seeded on glass coverslips into six-well plates at a
density of 1 10
5 cells per well in RPMI 1640 phenol-red-free
medium supplemented with 5% FCS and 2mML -glutamine.
Twenty-four hours later, cells were exposed to 5mM oxaliplatin,
20mgml
 1 cetuximab, or the combined treatment according to one
of three schedules of exposure: (1) 24-h exposure to oxaliplatin
followed by replacement of medium with drug-free medium until
analysis; (2) 24-h exposure to simultaneous oxaliplatin and
cetuximab followed by cetuximab exposure alone, renewed daily
until analysis; or (3) cetuximab alone, renewed daily until analysis.
At the indicated time in the figure legends, cells were fixed in
paraformaldehyde (3%), and nuclei were visualised by incubation
with DAPI (100mgml
 1). Cells were viewed on a Zeiss Axiophot
microscope (objective lenses  63) and pictures taken with a
Princeton camera. Results are representative of two independent
experiments in duplicate.
Phospho-AKT quantitation
The concentration of the phosphorylated form of AKT was
measured using a Pathscant Sandwich ELISA Kit (Cell Signaling
Technology, OZYME, Saint Quentin en Yvelines, France) following
the supplier’s instructions and expressed as the amount of
phosphorylated AKT related to the protein content (fmolmg
 1
of protein). Briefly, 1.5 10
6 cells were plated in 100-mm Petri
dishes, and 24h later, cells were exposed to 5mM oxaliplatin and/or
20mgml
 1 cetuximab for 24h. Cells were then harvested in lysis
buffer, and the level of phospho-AKT was quantified according to
the supplier’s protocol. The total protein quantity was determined
according to the Bradford method. Results are expressed as pg of
phospho-AKT per mg of total protein and represented as the
mean±s.e.m. of the variation factor of the phospho-AKT level
compared to the phospho-AKT level of untreated cells (variation
factor¼1) from three independent experiments.
Real-time PCR
A total of 2 10
6 exponentially growing cells were plated in 100-
mm Petri dishes and exposed for 24h to 5mM oxaliplatin,
20mgml
 1 cetuximab, or combination of both treatments. Then,
cells were washed twice with PBS, and total RNA was isolated using
Trizol solution (Invitrogen Life Technologies, Cergy Pontoise,
France). The quality and quantitation of each RNA sample were
determined by microchannel electrophoresis assay on the Agilent
2100
s Bioanalyser using the RNA NanoLab
s chip and the RNA
6000 Nano Assay
s kit (Agilent Technologies, Massy, France). A
total of 500ng of total RNA was reverse transcribed using the
iScriptt cDNA synthesis kit (Bio-Rad) according to the manu-
facturer’s instructions. Then, quantitative RT-PCR was performed
on an iCycler apparatus (Bio-Rad) using the SYBR Green
Jumpstart
s and Taq ReadyMix
s (Sigma) following the supplier’s
protocol. The sequences for the GAPDH and ERCC1 primers were
designed with Beacon designer software (Bio-Rad) and purchased
from Proligo (Sigma).
Excision repair cross complementation group1 expression
analysis: a total of 500ng of total RNA was reverse transcribed
using the iScript cDNA synthesis kit (Bio-Rad) according to the
manufacturer’s instructions. Quantitative RT-PCR was performed
on an iCycler apparatus (Bio-Rad) using the SYBR Green
Jumpstart and the Taq ReadyMix (Sigma) following the supplier’s
protocol. Briefly, the thermal cycling conditions included an initial
Taq polymerase activation (951C for 3min); the denaturation step
(40 cycles at 951C for 15s); the annealing and extension steps
(601C for 1min); and a melting curve analysis (incubation at 951C
for 10s, then slowly decreased to 201C). The GAPDH and ERCC1
primers (Proligo, Sigma) were as follows: (i) ERCC1 primers:
ERCC1 S5 0-GACCACAGGCTCCAGATGG-30; ERCC1 AS 50-
ATCCTCGTCGAGGGGTATCAC-30; (ii) GAPDH primers: GAPDH
S5 0-TGCACCACCAACTGCTTAGC-30, GAPDH AS 50-GGCATG-
GACTGTGGTCATGAG-30. To avoid amplification of contaminat-
ing genomic DNA, one of the two primers was designed to be
located at the junction between two exons or in a different exon.
First, we validated the PCR efficacy and specificity of the primers.
Then, we produced a standard curve with cDNA obtained from 0.1
to 20ng of total RNA to assess PCR efficacy and a melting curve to
check potential dimer formation. No dimers were observed, and
the calculated efficacy of PCR was between 0.95 and 1 for all tested
genes. Results are expressed as the mean±s.e.m. of at least three
independent experiments.
DNA replication and DNA repair factor expression analysis: a
total of 2mg of total RNA was reverse transcribed using the High-
Capacity cDNA Archive Kit (Applied Biosystems, APPLERA,
Courtaboeuf, France) as recommended by the supplier. Amplifica-
tion of the replication and repair factors was performed by real-
time PCR on the Applied Biosystems 7900HT Fast Real-Time PCR
System with the TaqMan
s Low Density Array screening technol-
ogy (Applied Biosystems) following the manufacturer’s protocol.
References of the primers and probes targeting the replication and
factors are as follows: CDC45L (ABI cat no. Hs00185895_m1),
CDC6 (ABI cat no. Hs00154374_m1), CDC7 (ABI cat no.
Hs00177487_m1), SLD5 (ABI cat no. Hs00260545_m1), MCM7
(ABI cat no. Hs00428518_m1), MCM8 (ABI cat no.
Hs00261182_m1), ASK (ABI cat no. Hs00272696_m1), DNA
polymerase a (ABI cat no. polA, Hs00213524_m1), CHK1 (ABI
cat no. Hs00176236_m1), Claspin (CLSPN, ABI cat no.
Hs00375405_m1), MCM2 (ABI cat no. Hs00170472_m1), RAD51
(ABI cat no. Hs00153418_m1), DNA polymerase-b (PolB, ABI cat
no. Hs00160263_m1), and mutL homologue 1 (MLH1) (ABI cat no.
Hs00179866_m1). To normalise gene expression between treated
and control samples, control genes (18S, GAPDH, HPRT, YWHAZ)
were also amplified with the same strategy (ABI cat no.
Hs9999901_s1, Hs4342376, Hs99999909_m1, Hs00237047_m1,
respectively). qBase software (http://medgen.ugent.be/qbase/) was
used to test the expression stability of the control genes. The two
most stable control genes, GAPDH and HPRT, were used by qBase
to normalise the expression values of all the replication and repair
targets.
Statistical analysis
All results are expressed as mean±s.e.m. Results were analysed
using Student’s t-tests, and Po0.05 was accepted as statistically
significant.
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Cetuximab increases and stabilises the level of platinum–
DNA adducts in HCT-8 but not in HCT-116 cells
The responsive HCT-8 and the non-responsive HCT-116 cell lines
were exposed for 24h to 5mM oxaliplatin with or without
20mgml
 1 cetuximab, and the DNA platination was then
determined by AAS. We found that the level of platinum–DNA
adducts in the HCT-8 cells increased by 19.4±3-fold when
cetuximab was combined with oxaliplatin (Po0.05), whereas no
significant differences in the rate of DNA platination were
observed for the HCT-116 cell line with the combined treatment
(Figure 1A). We then performed a kinetic experiment presented in
Figure 1B where we exposed HCT-8 and HCT-116 cells to 40mM
oxaliplatin for only 1h with or without cetuximab (20mgml
 1)
(T0) followed by a subsequent treatment with either vehicle or
20mgml
 1 cetuximab for 6 and 24h. No difference was observed in
either cell line in the platinum–DNA adduct content between
oxaliplatin exposure alone and oxaliplatin/cetuximab combination
at T0 and T¼6h. However, for the HCT-8 cells, the cetuximab
treatment resulted in a significant (Po0.001) persistence of DNA
platination after 24h (5.75±0.6pg Pt per mg DNA) compared to
the oxaliplatin-alone exposure (2.65±0.5pg Pt per mg DNA). This
outcome was not observed for the non-responsive HCT-116 cell
line. These data suggest that cetuximab could compromise the
DNA repair process of bulky platinum adducts in the responsive
HCT-8 cell line.
Oxaliplatin and/or cetuximab do not modulate GST activity
One of the cellular pathways involved in the modulation of DNA
platination is the detoxification activity of GST, which has a
cysteine residue that is very reactive with the platinum complex.
Thus, we determined whether cetuximab exposure in cells treated
with oxaliplatin enhances GST activity. HCT-8 and HCT-116 cells
were exposed 6 and 24h to cetuximab alone, oxaliplatin alone, or a
combination of both, and GST activity was determined as
described in Materials and Methods. For both cell lines, we failed
to find any difference in GST activity regardless of treatment,
demonstrating that the persistence of DNA platination in HCT-8
cells after the combined oxaliplatin/cetuximab treatment did not
result from hyperactivity of GST.
Combination oxaliplatin/cetuximab inhibits oxaliplatin-
induced overexpression of ERCC1 through transcriptional
regulation in HCT-8
Nucleotide excision repair is based on a cut-and-paste mechanism
requiring protein complexes that recognise the DNA damage
induced by platinum adduct, with helicases and nucleases that
remove the damaged strand, and DNA polymerases and ligases
that restore the correct sequence. One critical gene of NER is
ERCC1, which is involved in the 50 incision of the damage (Reed,
1998). Quantitative RT-PCR analysis of ERCC1, XPA, and XPD
expression were performed in HCT-8 cells that were either
untreated, exposed to oxaliplatin alone, or treated with a
combination of oxaliplatin/cetuximab (Figure 2A). For this relative
quantitation, we first identified the most stable housekeeping gene
among GAPDH, HPRT, and b-actin using the geNorm software.
Both b-actin and GAPDH were detected as stable with four cell
lines and under experimental conditions. Then normalisation was
performed using the DDCt method (Vandesompele et al, 2002)
with GAPDH as the housekeeping gene.
When the cells were exposed to either oxaliplatin or cetuximab
alone or to combination of both, neither XPA nor XPD exhibited
major modification (data not shown). On the contrary, when the
cells were exposed to oxaliplatin, a two-fold induction of the
ERCC1 transcript was observed (Figure 2A). This stimulation of
ERCC1 expression was confirmed at the protein level by western
blotting analysis (Figure 2B). Interestingly, we found that the
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Figure 1 Effect of oxaliplatin combined with cetuximab on platinum–DNA adduct formation and repair. DNA was extracted and platinum content was
measured by atomic absorption spectrophotometry. Quantitation of platinum–DNA adducts was performed after (A) exposure to either 5mM oxaliplatin
alone or combined with 20mgml
 1 cetuximab for 24h (n¼3); (B) exposure of the HCT-8 and HCT-116 cell lines for only 1h (T0) to 40mM oxaliplatin
alone (L-OHP, ) or combined with cetuximab (C225, ) and followed after medium change by either vehicle (&); or 20mgml
 1 cetuximab ( ) exposure
for 6 and 24h (n¼6). Dilution effect of proliferation on the DNA adduct content was corrected by [
3H]-thymidine incorporation. Values are mean±s.e.m.
of at least three independent experiments. ***Po0.005; *Po0.05. Student’s t-test compared to oxaliplatin alone.
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scombined oxaliplatin/cetuximab treatment induced a clear and
strong reduction of ERCC1 expression both at the mRNA and
protein levels in the responding HCT-8 cells (Figure 2A and B) and
not in the non-responsive HCT-116 cells. These results support the
fact that cetuximab treatment in HCT-8 cells could elicit a loss of
ERCC1 activity and prevent excision of platinum adducts from
DNA, a process that may account for the responsiveness of this cell
line.
Oxaliplatin/cetuximab combination induced a dramatic
decrease in cells in the S phase and enrichment in the G1
and G2/M phases in HCT-8 cells
To evaluate the portion of cells engaged in DNA processing at
exposure, the effects on cell cycle distribution of each drug alone
and combined were assessed in both the HCT-8 and HCT-116 cell
lines (Figure 3). The 24-h exposure of HCT-8 cells to cetuximab or
oxaliplatin alone induced a significant increase in cells in the G0/
G1 phase from 57.9±0.1% for the untreated condition to 74.6±6.2
and 64.2±1.7%, respectively, when cells were treated with
cetuximab or oxaliplatin. Moreover, oxaliplatin also induced an
accumulation of cells in the G2/M phase (25.0±1.4 vs 14.6±2.7%
for untreated cells). The combination of cetuximab with oxaliplatin
resulted in the manifestation of both effects, an increase in the
number of the cells in G0/G1 and G2/M phases (69.3±1.2 and
21.1±2.9%, respectively, vs 57.9±0.1 and 14.6±2.7% for the
untreated condition) with a concomitant decrease in the number
of cells in the S phase (9.6±1.7 vs 27.2±3.2% for untreated cells).
Furthermore, kinetics evaluation of cell cycle progression until
72h (Figure 3B) showed that oxaliplatin exposure led to the
maintenance of the blockade through the G0/G1 and G2/M phases
(64.3±1.8 and 30.9±1.5% vs 58.0±0.1 and 14.6±2.7% for
untreated cells at 24h) associated with a strong decrease in the
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Figure 2 Effect of cetuximab, oxaliplatin, and the combination of both
on ERCC1 expression at the mRNA and protein levels in the HCT-8 cell
line. (A) Relative quantitation of ERCC1 mRNA was performed with
GAPDH as the housekeeping gene and untreated cells as control reference.
HCT-8 cells were exposed to 20mgml
 1 cetuximab (C225, &), 5mM
oxaliplatin (L-OHP, ), or a combination of both (’) for 6 and 24h.
Results are expressed as the mean±s.e.m. of three independent
experiments. (B) Western blot analysis of ERCC1 protein expression
after 24h exposure to 5mM oxaliplatin, 20mgml
 1 cetuximab, or a
combination of both drugs and representative of three independent
experiments. *Po0.05 Student’s t-test compared to the effect of
oxaliplatin alone.
Time Drug exposure
Control
24 h C225
L-OHP
L-OHP+C225
Control
48 h C225
L-OHP
L-OHP+C225
Control
72 h C225
L-OHP
L-OHP+C225
50.1 ±6.4 34.2±6.2 15.8±0.2
49.3 ±5.2 35.1±4.6 15.7±0.6
49.9 ±3.4 4.3±1.3 45.8±2.1
46.5 ±2.3 5.8±0.2 47.8±2.1
66.3 ±3.6 20.2±3.5 13.5±0.1
68.0 ±2.6 19.3±2.3 12.8±0.4
45.7 ±2.7 4.0±0.7 50.4±3.3
48.4 ±1.2 5.2±1.8 47.6±1.2
66.4 ±1.7 24.5±2.0 9.2±0.3
68.1 ±3.8 22.0±1.4 9.9±2.4
45.3 ±0.8 8.7±1.1 46.0±0.4
58.0±0.1
74.6±6.2
64.2±1.7
69.3±1.2
60.3±3.5
71.1±3.4
64.8±1.1
69.8±1.0
65.5±3.5
69.8±4.5
64.3±1.8
69.3±3.5
27.2 ±3.2
15.4 ±1.6
10.5 ±0.2
9.6 ±1.7
25.6 ±4.6
17.4 ±0.8
7.3 ±5.2
5.1 ±2.4
20.0 ±9.0
20.9 ±5.1
5.5 ±1.4
6.4 ±0.1
14.6 ± 2.7
9.8 ± 4.8
25.0 ± 1.4
21.1 ± 2.9
14.2 ± 1.2
11.5 ± 4.2
28.0 ± 4.2
25.1 ± 3.4
9.0 ± 1.4
9.3 ± 0.6
30.9 ± 1.5
26.5 ± 0.6 44.5 ±1.8 8.7±0.5 46.8±1.4
SG 2/M
HCT8 HCT116
G1 S G2/M G1
Control
L-OHP
C225
LOHP-C225
HCT-116 HCT-8
Control
L-OHP
C225
LOHP-C225
A
B
Figure 3 Effect of cetuximab, oxaliplatin, or combination exposure on cell cycle repartition of HCT-8 and HCT-116 cell lines. The cell cycle distribution of
HCT-8 and HCT-116 cells was determined after (A) 24h exposure to drug-free medium ( ), 20mgml
 1 cetuximab (C225, ), 5mM oxaliplatin alone (L-
OHP, ), or a combination of both ( ). (A representative experiment of three independent assessments is shown), and (B) kinetic evolution until 72h of
the percent of cells in G0/G1, S, and G2/M phases after exposure to either vehicle (control), 20mgml
 1 cetuximab daily (C225), 5mM oxaliplatin for 24h
followed by drug-free medium (L-OHP), or the combined treatment of oxaliplatin plus cetuximab for 24h followed by 20mgml
 1 cetuximab daily (L-
OHPþC225). Results are expressed as the mean±s.e.m. of three independent experiments.
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snumber of cells in the S phase (5.5±1.4 vs 27.2±3.2% for control
cells at 24h). This cell cycle modification persisted to the 72-h time
point.
In the HCT-116 cell line, oxaliplatin exposure induced an arrest
in the G2/M phase from 24h (45.8±2.1 vs 15.8±0.2% for
untreated cells) to 72h (46.0±0.4 vs 9.2±0.3% for untreated
cells) resulting in a strong decrease in the number of cells in the S
phase up to 72h (8.7±0.5 vs 24.5±2.0% for control cells).
Cetuximab alone had no effect; consequently, the effect from the
combination of both drugs was assumed to be an effect of
oxaliplatin alone.
Oxaliplatin/cetuximab combination promotes an early
apoptotic effect and inhibits survival through
downregulation of AKT activation in HCT-8 cells
We next studied the putative effect of cetuximab and/or oxaliplatin
exposure on the morphology of cellular nuclei through detection
of an apoptotic pattern of chromatin condensation and nuclear
DNA fragmentation using DAPI fluorescent staining (Figure 4A).
No significant apoptotic effect of cetuximab alone was observed
for any cell line or treatment. HCT-8 cells treated with oxaliplatin
displayed at t¼48h typical morphological features of apoptotic
cells with condensed and fragmented nuclei. When oxaliplatin
was combined with cetuximab, these features were observed at
t¼24h, suggesting that the proapoptotic effect of oxaliplatin
occurs 24h earlier when combined with cetuximab. No differences
were observed between oxaliplatin alone and combined with
cetuximab in the HCT-116 cells. Obviously, for both cell lines,
the cytotoxic effect of oxaliplatin was still present; this was
characterised from the first 24h and during the time course
treatment by a decrease in the cell number, as visualised by
fluorescent microscopy.
Because the PI3K/AKT pathway is a key point in the regulation
of the balance between survival and apoptosis downstream of the
signal transduction pathway regulated by EGFR, we performed
quantification of the phosphorylated form of AKT to assess
survival regulation in the cell lines after exposure to cetuximab
and/or oxaliplatin (Figure 4B). In HCT-8 cells, oxaliplatin induced
a significant induction of phospho-AKT levels by 1.9±0.2 (relative
expression), which was significantly inhibited by the simultaneous
exposure to cetuximab (Po0.05). On the other hand, in the HCT-
116 cell line, we observed no difference between the effect on the
phospho-AKT level of oxaliplatin alone or combined with
cetuximab.
Cetuximab enhances oxaliplatin-induced downregulation
of multiple targets involved in DNA replication,
recombination, and repair
In addition to the NER pathway, many other potential DNA
interactions manage resistance to platinum damage. These
mechanisms include regulation of DNA replication by specialised
DNA polymerases, mismatch repair, or recombination repair.
Therefore, we performed a large-scale RT-QPCR analysis using
low-density array technology to compare the transcriptional
response between HCT-116 and HCT-8 cells after drug exposure.
We assessed expression of multiple target genes involved in these
adaptive or repair pathways as well as genes regulating the S-phase
progression during the cell cycle (Figure 5). For each cell line,
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HCT-116
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Figure 4 Proapoptotic effect of the oxaliplatin/cetuximab combination. (A) HCT-8 and HCT-116 cells were exposed to 5mM oxaliplatin (L-OHP) or
5mM oxaliplatin plus 20mgml
 1 cetuximab (L-OHPþC225) for 24h. Cells were then stained with DAPI to visualise the nuclear morphology and to detect
any pattern of chromatin condensation and nuclear DNA fragmentation that characterises apoptotic cells (a representative experiment of three
independent assessments is shown). (B) Quantitation of phosphorylated AKT variations in HCT-8 and HCT-116 cells after 24h exposure to 20mgml
 1
cetuximab (&), 5mM oxaliplatin ( ), or a combination of both (’) compared to untreated cells. Results are expressed as the mean±s.e.m. of three
independent experiments. *Po0.05. Student’s t-test compared to the effect of oxaliplatin alone.
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sresults are presented as the mRNA expression ratio between
treated and untreated conditions. Results highlight very different
profiles of response to oxaliplatin exposure between HCT-116 and
HCT-8 cells (Figure 5), but cetuximab alone had no effect in these
cell lines. Except for PolB and human MLH1 genes, which were not
significantly modulated in the two cell lines, oxaliplatin induced a
more important downregulation of the replication and repair
factors in HCT-8 than in HCT-116. The combination of the two
treatments in HCT-8 tended to increase the downregulation of
targets, and the effect was particularly obvious regarding Claspin,
CDC45, and CDC6 expressions, three major proteins involved in
DNA replication initiation.
CDC45L, CDC6, CDC7, SLD5, MCM7, ASK, polA, and MCM2 are
all implicated in the initiation of DNA replication and their
downregulation might be reflected in the blockade in the G1 phase
of the cell cycle observed in the previously described experimental
results.
DISCUSSION
We previously demonstrated that cetuximab sensitised some
colorectal cancer cell lines to the platinum-derived drug oxaliplatin
(Balin-Gauthier et al, 2006). In the present study, we used the
HCT-8 and HCT-116 cell lines to investigate the cellular and
molecular mechanisms and pathways involved in the synergistic
response to oxaliplatin/cetuximab combination observed in the
HCT-8 cell line compared to the non-responsive HCT-116 cell line.
The HCT-8 and HCT 116 cell lines are well characterised in their
mutation status of K-RAS, B-RAF, and EGFR and alteration of
EGFR gene copy number (CISH study, data not shown), implicated
with anti-EGFR mAbs response. HCT-8 cells have a wild-type
status concerning K-RAS, B-RAF, and EGFR genes and are not
amplified for EGFR (Balin-Gauthier et al, 2006; Benvenuti et al,
2007), whereas HCT-116 cells are K-RAS mutated, B-RAF wild type
and EGFR wild type and non-amplified (Balin-Gauthier et al, 2006;
Benvenuti et al, 2007).
In the responsive HCT-8 colorectal cancer cell line, cetuximab
induces the stimulation of platinum–DNA adduct formation. This
upregulation is associated with reduced expression of the NER key
factor ERCC1, both at the mRNA and protein levels. Moreover, we
observed a reduced expression of factors involved in DNA
replication initiation, which correlates with an enrichment of cells
in the G1 phase of the cell cycle plus the stimulation of the
apoptosis pathway outcome with an acceleration of apoptosis.
None of these changes occurred in the non-responsive HCT-116
cell line, pointing out multiple interactions between oxaliplatin
pharmacology and the EGFR signalling transduction pathway.
Finally, the analysis of the gene expression modulation highlights
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Figure 5 Multigene analysis of cetuximab, oxaliplatin, or a combination of both on expression of multiple genes involved in DNA replication, repair, and
recombination. (A) Reverse transcription quantitative PCR analysis was performed on various genes involved in DNA repair, replication, and recombination
in HCT-8 and HCT-116 cells exposed to either 20mgml
 1 cetuximab (C225), 5mM oxaliplatin (L-OHP), or a combination of both (Combo) for 24h. Gene
expression variation factors o2( ) and increased effect of oxaliplatin by more than 30% (’) when combined with cetuximab are represented. (B) Focus
on relative expression of genes involved in the initiation of DNA replication after 24h exposure to 20mgml
 1 cetuximab (&), 5mM oxaliplatin ( ), or a
combination of both (’). To normalise gene expression between treated and control samples, control genes of GAPDH and HPRT were used. Relative
quantitation of mRNA expression of each gene was performed in triplicate.
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sthe inhibition of DNA replication initiation as a signature of
oxaliplatin/cetuximab synergistic interaction.
When a synergistic interaction occurred between oxaliplatin and
cetuximab in HCT-8 cells, platinum–DNA adduct formation
increased by 20%, suggesting two different but possibly linked
mechanisms. What was unknown was whether cetuximab inhibits
the oxaliplatin detoxification pathway and/or cetuximab inhibits
the DNA–platinum adduct repair pathway. Thus, we studied these
two possibilities. Because the major system of oxaliplatin
detoxification uses the GSH cycle through activation of GSTs
(Pendyala and Creaven, 1993), we investigated the effect of drug
exposure on GST activity. Because any drug alone or in
combination did not induce any modulation of GST activity, we
focused on oxaliplatin–DNA adduct repair whose main cellular
process is the NER.
When HCT-8 cells were exposed to a strong dose of oxaliplatin
in combination with cetuximab, the level of adduct stabilised 24-h
after exposure termination, but it continuously decreased under
exposure to oxaliplatin alone. Moreover, these results are
consistent with those of Xu et al (2003), demonstrating that
gefitinib, a tyrosine kinase inhibitor of EGFR, modestly enhanced
cellular oxaliplatin accumulation and platinum–DNA adduct
levels and significantly inhibited removal of Platinum–DNA
adducts. Taken together, our results and those of previously
published works suggest that inhibition of the EGFR pathway may
stabilise platinum–DNA adduct content through inhibition of
platinum–DNA adduct repair.
Nucleotide excision repair is the main DNA repair mechanism
involved in oxaliplatin–DNA adduct repair (Reed, 1998; Chaney
et al, 2005). This mechanism is associated with adduct recognition
proteins such as XPA and XPC (xeroderma pigmentosum A and C:
DNA-lesion recognition proteins) and with proteins such as
ERCC1, which catalyses excision of the damaged nucleotide.
Because ERCC1 catalyses the 50 incision at the damage site (Reed,
1998), its expression and functionality are crucial for NER activity.
Moreover, its overexpression has been reported to be correlated
with oxaliplatin resistance (Arnould et al, 2003). Thus, we
investigated whether the NER could be targeted by the combined
treatment of oxaliplatin plus cetuximab through the regulation of
ERCC1 and XPA expression at the translational and transcriptional
levels.
Unlike studies demonstrating that ERCC1 basal level could
predict the effect of oxaliplatin alone (Raymond et al, 2002), in our
study, this level was similar between HCT-116 and HCT-8 cells
(data not shown) and thus could not predict a synergistic
interaction between oxaliplatin and cetuximab. However, we have
shown that oxaliplatin induces a two-fold upregulation of ERCC1
mRNA and protein expression in HCT-8 but not in HCT-116 cells.
It has been reported that oxaliplatin induces ERCC1 expression in
cell lines that display resistance to platinum drugs (Youn et al,
2004). We demonstrated that the oxaliplatin/cetuximab combina-
tion inhibits the oxaliplatin-induced upregulation of ERCC1
observed in HCT-8 cells. This inhibition of expression is observed
both at the mRNA and protein levels, suggesting that the
cetuximab/oxaliplatin combination inhibits ERCC1 induction and
consequently NER activity through this transcriptional regulation.
These data also suggest that the sensitisation of HCT-8 cells to
oxaliplatin under cetuximab exposure is partly the result of
inhibition of the main mechanism implicated in the repair of
platinum–DNA adducts. The EGFR pathway could control the
regulation of ERCC1 expression and thus oxaliplatin resistance.
We know that the EGFR signalling pathway can regulate
transcription through the activation of oncogene transcription
factors such as c-jun, c-myc, and c-fos (Yarden, 2001). Interest-
ingly, ERCC1 gene transcription can be regulated by the AP-1
transcription factor (c-Fos and c Jun dimer) that binds to its
promoter region (Youn et al, 2004), involving this factor in the
mechanisms of oxaliplatin resistance.
Deficiency of DNA repair drives cells to undergo apoptosis,
which led us to study the putative effect of cetuximab and/or
oxaliplatin exposure on this specific cell death process. In HCT-8
cells exposed to oxaliplatin/cetuximab, morphologic changes
associated with apoptosis (DNA condensation and fragmentation)
occurred 24h earlier than in cells exposed to oxaliplatin alone and
could play a role in the enhanced antiproliferative effects that we
observed previously (Chaney et al, 2005). In HCT-8 cells,
oxaliplatin exposure promoted survival through AKT activation;
cetuximab exposure concomitant with oxaliplatin inhibited this
regulation and induced restoration of apoptosis through the
inhibition of oxaliplatin-induced AKT activation. On the other
hand, when the non-responsive HCT-116 cells were exposed to
oxaliplatin either alone or combined with cetuximab, we observed
similar nucleic morphologic changes. At the same time, no effect
on AKT phosphorylation was observed in this cell line. Because
activation of survival through the PI3K/AKT pathway is one
mechanism by which cells can resist to cytotoxic drug exposure
(Kim et al, 2005), such data suggest that the inhibition of AKT
activation and related effects on apoptosis could be part of the
HCT-8 synergistic response to the oxaliplatin/cetuximab combina-
tion. On the other hand, in HCT-116, a K-Ras mutated cell line,
EGF-R inhibition had no effect either on the MAPK pathway (data
not shown) or on AKT phosphorylation. This lack of effect could
explain the lack of efficacy of cetuximab in K-Ras-mutated
colorectal cancer (Benvenuti et al, 2007).
Experiments addressing cell cycle regulation showed that
cetuximab treatment induced a weak (10%) enrichment in the
G0/G1 phase only in the HCT-8 cell line. These results are
consistent with those in the literature, including our previous work
(Kiyota et al, 2002; Chaney et al, 2005), in which we reported that
EGFR inhibitors are generally characterised by a cytostatic effect
associated with enrichment of the G0/G1 phase of the cell cycle.
Moreover, for each cell line, we showed that the effects on cell cycle
of oxaliplatin/cetuximab together are additive of the effect of each
molecule used alone.
Our results led us to extend our study to multiple gene analysis
of targets implicated in DNA repair, replication, and recombina-
tion. The results of these studies suggested that under oxaliplatin
treatment, the presence of the oxaliplatin adducts prevents the
firing of new replication origins, explaining the low number of
cells in the S phase. Such inhibition of licensing or replication
initiation could prevent cells from duplicating long patches of
DNA and consequently promote DNA translesion or homologous
recombination repair to process DNA damage. In our models,
cetuximab alone had no effect in downregulation mechanisms of
replication initiation. On the other hand, when used in combina-
tion with oxaliplatin, it modified oxaliplatin adduct repair and
induced modifications in the early steps of DNA replication in the
HCT-8 cell line. To conclude, the present study shows for the first
time that inhibition of the EGFR transduction pathway by
cetuximab sensitises cells to oxaliplatin via the downregulation
of mechanisms implicated in oxaliplatin resistance. The character-
istics of the synergistic response to the oxaliplatin/cetuximab
combination in the HCT-8 cell line led us to highlight the
importance of DNA replication initiation as a critical step that
could be a molecular signature of response to this combination.
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